FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014946273> ?p ?o ?g. }

• W2014946273 endingPage "2484" @default.
• W2014946273 startingPage "2477" @default.
• W2014946273 abstract "Heme oxygenase-1 (HO-1) has potent anti-inflammatory activity and recognized vascular protective effects. We have recently described the expression and vascular protective effects of an anti-inflammatory interleukin (IL-19), in vascular smooth muscle cells (VSMC) and injured arteries. The objective of this study was to link the anti-inflammatory effects of IL-19 with HO-1 expression in resident vascular cells. IL-19 induced HO-1 mRNA and protein in cultured human VSMC, as assayed by quantitative RT-PCR, immunoblot, and ELISA. IL-19 does not induce HO-1 mRNA or protein in human endothelial cells. IL-19 activates STAT3 in VSMC, and IL-19-induced HO-1 expression is significantly reduced by transfection of VSMC with STAT3 siRNA or mutation of the consensus STAT binding site in the HO-1 promoter. IL-19 treatment can significantly reduce ROS-induced apoptosis, as assayed by Annexin V flow cytometry. IL-19 significantly reduced ROS concentrations in cultured VSMC. The IL-19-induced reduction in ROS concentration is attenuated when HO-1 is reduced by siRNA, indicating that the IL-19-driven decrease in ROS is mediated by HO-1 expression. IL-19 reduces vascular ROS in vivo in mice treated with TNFα. This points to IL-19 as a potential therapeutic for vascular inflammatory diseases and a link for two previously unassociated protective processes: Th2 cytokine-induced anti-inflammation and ROS reduction. Heme oxygenase-1 (HO-1) has potent anti-inflammatory activity and recognized vascular protective effects. We have recently described the expression and vascular protective effects of an anti-inflammatory interleukin (IL-19), in vascular smooth muscle cells (VSMC) and injured arteries. The objective of this study was to link the anti-inflammatory effects of IL-19 with HO-1 expression in resident vascular cells. IL-19 induced HO-1 mRNA and protein in cultured human VSMC, as assayed by quantitative RT-PCR, immunoblot, and ELISA. IL-19 does not induce HO-1 mRNA or protein in human endothelial cells. IL-19 activates STAT3 in VSMC, and IL-19-induced HO-1 expression is significantly reduced by transfection of VSMC with STAT3 siRNA or mutation of the consensus STAT binding site in the HO-1 promoter. IL-19 treatment can significantly reduce ROS-induced apoptosis, as assayed by Annexin V flow cytometry. IL-19 significantly reduced ROS concentrations in cultured VSMC. The IL-19-induced reduction in ROS concentration is attenuated when HO-1 is reduced by siRNA, indicating that the IL-19-driven decrease in ROS is mediated by HO-1 expression. IL-19 reduces vascular ROS in vivo in mice treated with TNFα. This points to IL-19 as a potential therapeutic for vascular inflammatory diseases and a link for two previously unassociated protective processes: Th2 cytokine-induced anti-inflammation and ROS reduction." @default.
• W2014946273 created "2016-06-24" @default.
• W2014946273 creator A5001908946 @default.
• W2014946273 creator A5002745087 @default.
• W2014946273 creator A5005917520 @default.
• W2014946273 creator A5013940811 @default.
• W2014946273 creator A5014225071 @default.
• W2014946273 creator A5052851159 @default.
• W2014946273 creator A5085473478 @default.
• W2014946273 date "2012-01-01" @default.
• W2014946273 modified "2023-10-16" @default.
• W2014946273 title "Interleukin-19 (IL-19) Induces Heme Oxygenase-1 (HO-1) Expression and Decreases Reactive Oxygen Species in Human Vascular Smooth Muscle Cells" @default.
• W2014946273 cites W1489079707 @default.
• W2014946273 cites W1551093971 @default.
• W2014946273 cites W1946768698 @default.
• W2014946273 cites W1973376761 @default.
• W2014946273 cites W1979672764 @default.
• W2014946273 cites W1979851632 @default.
• W2014946273 cites W1986430910 @default.
• W2014946273 cites W1998426806 @default.
• W2014946273 cites W2003350590 @default.
• W2014946273 cites W2003614722 @default.
• W2014946273 cites W2009183800 @default.
• W2014946273 cites W2014002468 @default.
• W2014946273 cites W2020941408 @default.
• W2014946273 cites W2020957744 @default.
• W2014946273 cites W2026273230 @default.
• W2014946273 cites W2026873822 @default.
• W2014946273 cites W2030117457 @default.
• W2014946273 cites W2035976778 @default.
• W2014946273 cites W2043808211 @default.
• W2014946273 cites W2044895999 @default.
• W2014946273 cites W2044951483 @default.
• W2014946273 cites W2058136294 @default.
• W2014946273 cites W2066963386 @default.
• W2014946273 cites W2083802827 @default.
• W2014946273 cites W2121149365 @default.
• W2014946273 cites W2128304597 @default.
• W2014946273 cites W2133150758 @default.
• W2014946273 cites W2141077451 @default.
• W2014946273 cites W2147564573 @default.
• W2014946273 cites W2148308989 @default.
• W2014946273 cites W2151158739 @default.
• W2014946273 cites W2154276482 @default.
• W2014946273 cites W2155729092 @default.
• W2014946273 cites W2161262137 @default.
• W2014946273 cites W2164998950 @default.
• W2014946273 cites W2167866149 @default.
• W2014946273 cites W2170662335 @default.
• W2014946273 cites W2324841714 @default.
• W2014946273 doi "https://doi.org/10.1074/jbc.m111.312470" @default.
• W2014946273 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3268408" @default.
• W2014946273 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22158875" @default.
• W2014946273 hasPublicationYear "2012" @default.
• W2014946273 type Work @default.
• W2014946273 sameAs 2014946273 @default.
• W2014946273 citedByCount "41" @default.
• W2014946273 countsByYear W20149462732012 @default.
• W2014946273 countsByYear W20149462732013 @default.
• W2014946273 countsByYear W20149462732014 @default.
• W2014946273 countsByYear W20149462732015 @default.
• W2014946273 countsByYear W20149462732016 @default.
• W2014946273 countsByYear W20149462732018 @default.
• W2014946273 countsByYear W20149462732019 @default.
• W2014946273 countsByYear W20149462732020 @default.
• W2014946273 countsByYear W20149462732021 @default.
• W2014946273 countsByYear W20149462732022 @default.
• W2014946273 crossrefType "journal-article" @default.
• W2014946273 hasAuthorship W2014946273A5001908946 @default.
• W2014946273 hasAuthorship W2014946273A5002745087 @default.
• W2014946273 hasAuthorship W2014946273A5005917520 @default.
• W2014946273 hasAuthorship W2014946273A5013940811 @default.
• W2014946273 hasAuthorship W2014946273A5014225071 @default.
• W2014946273 hasAuthorship W2014946273A5052851159 @default.
• W2014946273 hasAuthorship W2014946273A5085473478 @default.
• W2014946273 hasBestOaLocation W20149462731 @default.
• W2014946273 hasConcept C134018914 @default.
• W2014946273 hasConcept C153911025 @default.
• W2014946273 hasConcept C181199279 @default.
• W2014946273 hasConcept C185592680 @default.
• W2014946273 hasConcept C203014093 @default.
• W2014946273 hasConcept C2776217839 @default.
• W2014946273 hasConcept C2776914184 @default.
• W2014946273 hasConcept C2778690821 @default.
• W2014946273 hasConcept C2779219270 @default.
• W2014946273 hasConcept C2779395532 @default.
• W2014946273 hasConcept C2992686903 @default.
• W2014946273 hasConcept C48349386 @default.
• W2014946273 hasConcept C553184892 @default.
• W2014946273 hasConcept C55493867 @default.
• W2014946273 hasConcept C86803240 @default.
• W2014946273 hasConcept C88634738 @default.
• W2014946273 hasConcept C95444343 @default.
• W2014946273 hasConceptScore W2014946273C134018914 @default.
• W2014946273 hasConceptScore W2014946273C153911025 @default.
• W2014946273 hasConceptScore W2014946273C181199279 @default.
• W2014946273 hasConceptScore W2014946273C185592680 @default.
• W2014946273 hasConceptScore W2014946273C203014093 @default.

• next